Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
Clinical trial NCT02140333 · UNKNOWN
Trial details
- NCT number
- NCT02140333
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-08-01
- Primary completion
- 2018-08-01
- Enrollment
- 220
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.